This opportunity is no longer accepting applications.
grant PAR-22-216

NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)

This grant opportunity supports early-stage, exploratory research in cancer field, focusing on diagnosis, treatment, imaging, symptom/toxicity, and prevention. It encourages new approaches in clinical trials, including developing novel cancer therapies and preclinical studies using innovative models and imaging technologies. The goal is to promote high-risk, high-reward projects that could lea…

This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and prevent…

Funding Source

Agency: National Institutes of Health
Program: SBIR

Awards & funding

Award Ceiling: $275,000
Award Amount: $275,000

Dates

Submission Deadline: July 1, 2025
Application Window Closes: July 1, 2025
Opportunity Released: July 14, 2022
Open for Submission: July 14, 2022

Documents

Secure Grant Funding 10x Faster

Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.

Already have an account? Sign In

Trusted by 500+ Happy Customers

Get opportunities sent to your inbox

The latest grant news and insights from our experts.

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.